This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula (IA) or (IB) or a salt, or N-oxide, ~~hydrate or solvate~~ thereof:



(IA)



(IB)

wherein

Ar is an aryl or heteroaryl radical which is linked via a ring carbon, and which is substituted by a hydroxy group on a carbon in the 2-position, and which is otherwise either unsubstituted or optionally substituted;

R_1 is hydrogen or optionally substituted C_1-C_6 alkyl;

R_2 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C_1-C_6 alkyl, C_1-C_6 alkenyl, or C_1-C_6 alkynyl ; or a carboxyl, carboxamide or carboxyl ester group; and;

R_3 is a carboxamide group.

2. (Original) A compound as claimed in claim 1 wherein Ar is a 2-hydroxyphenyl group which is optionally further substituted.

3. (Original) A compound as claimed in claim 1 wherein Ar is a 2-hydroxyphenyl group further

substituted by one or more of hydroxy, ethyl, isopropyl, chloro, bromo, or phenyl groups.

4. (Original) A compound as claimed in claim 1 wherein Ar is a 2,4-dihydroxy-5-chlorophenyl group.

5. (Previously Presented) A compound as claimed in claim 1 wherein R_1 and R_2 are independently hydrogen, methyl, ethyl, n- or iso-propyl, or hydroxyethyl.

6. (Previously Presented) A compound as claimed claim 1 wherein R_1 is hydrogen and R_2 is hydrogen or methyl.

7. (Previously Presented) A compound as claimed claim 1 wherein R_3 is a carboxamide group of formula $-CONR^B(Alk)_nR^A$ wherein

Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical,

n is 0 or 1,

R^B is hydrogen or a C_1-C_6 alkyl or C_2-C_6 alkenyl group

R^A is hydroxy or an optionally substituted carbocyclic or heterocyclic group.

8. (Original) A compound as claimed in claim 7 wherein Alk is-CH_2-, -CH_2CH_2-, -$CH_2CH_2CH_2$-, -CH_2CH=CH-, or-CH_2CCCH_2-, R^B is hydrogen or methyl, ethyl, n-or iso-propyl, or allyl, and R^A is hydroxy or optionally substituted phenyl, pyridyl, furyl, thienyl, N-piperazinyl, or N-morpholinyl.

9. (Previously Presented) A compound as claimed in claim 7 wherein R^A is phenyl, optionally substituted by at least one of OH, CH_3O-, Cl, F, NH_2CO-, NH_2CO-, CH_3NHCO- -COOH, -$COOCH_3$, -CH_2COOH, -CH_2COOCH_3, -CH_3, -CF_3, - SO_2CH_3, -SO_2NH_2, 3,4-methylenedioxy

and 3,4-ethylenedioxy.

10. (Previously Presented) A compound as claimed in any claim 7 wherein R_1 and R_2 are hydrogen, Ar is a 2,4-dihydroxy-5-chlorophenyl group, Alk is-CH_2-, n is 0 or 1, R^B is hydrogen, and R^A is phenyl, optionally substituted by at least one of OH, CH_3O-, Cl, F, NH_2CO-, NH_2CO-, CH_3NHCO-, -COOH, -$COOCH_3$, -CH_2COOH, -CH_2COOCH_3, -CH_3, -CF_3, -SO_2CH_3, -SO_2NH_2, 3,4-methylenedioxy and 3,4-ethylenedioxy.

11. (Original) A compound as claimed in claim 7 wherein R^A and R^B taken together with the nitrogen to which they are attached form an N-heterocyclic ring which optionally contains one or more additional hetero atoms selected from O, S and N, and which is optionally substituted on one or more ring C or N atoms.

12. (Original) A compound as claimed in claim 11 wherein R^A and R^B taken together with the nitrogen to which they are attached form amorpholino, piperidinyl, piperazinyl or N-phenylpiperazinyl ring, which is optionally substituted on one or more ring C or N atoms.

13. (Previously Presented) A compound as claimed in claim 1 ~~which is a member of~~ selected from the group consisting of
3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-acetyl-phenyl)-amide,
3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid phenyl-amide,
3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-methoxy-phenyl)-amide,
3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-chloro-phenyl)-amide,
3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-acetylamino-phenyl)-amide,
3-(5-Chloro-2,4-dihydroxy-phenyl)-l H-pyrazole-4-carboxylic acid 4-sulfamoyl-benzylamide,
3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-methoxy-phenyl)-amide,
3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-chloro-phenyl)-amide,
3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid (4-acetylamino-phenyl)-amide,

3-(5-Chloro-2,4-dihydroxy-phenyl)-l H-pyrazole-4-carboxylic acid 4-sulfamoyl-benzylamide,
3-(5-Chloro-2,4-dihydroxy-phenyl)-l H-pyrazole-4-carboxylic acid (4-carbamoyl-phenyl)-amide,
4-({[3-(5-Chloro-2,4-dihydroxy-phenyl)-l H-pyrazole-4-carbonyl]-amino]=methyl)-benzoic acid,
3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid 4-methyl-benzylamide,
3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid 4-methoxy-benzylamide,
3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid 4-fluoro-benzylamide,
3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid 4-chloro-benzylamide,
3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid 3-methoxy-benzylamide,
3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid 3-trifluoromethyl-benzylamide,
3-(5-Chloro-2,4-dihydroxy-phenyl)-1H-pyrazole-4-carboxylic acid 4-methanesulfonyl-benzylamide,
and salts, and N-oxides, ~~hydrates and solvates~~ thereof.

14. (Withdrawn) A method of treatment of diseases or conditions responsive to inhibition of HSP90 activity in mammals comprising administering to the mammal an effective amount of a compound as claimed in claim 1.

15. (Previously Presented) A human or veterinary medicine comprising the compound as claimed in claim 1.

16. (Previously Presented) The medicine of claim 15 for the treatment of diseases or conditions responsive to inhibition of HSP90 activity.

17. (Canceled)

18. (Withdrawn) A method as claimed in claim 14 wherein the disease or condition is cancer.

19. (Withdrawn) A method as claimed in claim 14 wherein the disease or condition is a viral disease, transplant rejection, inflammatory disease, asthma, multiple sclerosis, Type I diabetes,

lupus, psoriasis, inflammatory bowel disease, cystic fibrosis, angiogenesis-related disease, diabetic retinopathy, haemangioma, or endometriosis.

20. (Withdrawn) A method as claimed in claim 14 wherein the mammals are humans.